{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:17:52Z","timestamp":1787314672189,"version":"build-2736575974"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jhep.2025.10.022","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:42:29Z","timestamp":1762274549000},"page":"13-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase II clinical trials in primary sclerosing cholangitis: Making the most of every opportunity?"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8941-6170","authenticated-orcid":false,"given":"David N.","family":"Assis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5900-8096","authenticated-orcid":false,"given":"Johannes R.","family":"Hov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.10.022_bib1","first-page":"671","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.022_bib2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/HEP.0000000000001172","article-title":"Medical treatment of primary sclerosing cholangitis: what have we learned and where are we going?","volume":"82","author":"Karlsen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.10.022_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jhep.2025.04.025","article-title":"Safety and efficacy of elafibranor in primary sclerosing cholangitis: the ELMWOOD phase II randomized-controlled trial","volume":"84","author":"Levy","year":"2026","journal-title":"J Hepatol"},{"issue":"309","key":"10.1016\/j.jhep.2025.10.022_bib4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1056\/NEJMe2313802","article-title":"PPAR agonists in primary biliary cholangitis","volume":"29","author":"Schnabl","year":"2024","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jhep.2025.10.022_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cells13151296","article-title":"PPAR-mediated bile acid glucuronidation: therapeutic targets for the treatment of cholestatic liver diseases","volume":"13","author":"Gallucci","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.jhep.2025.10.022_bib6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.10.022_bib7","series-title":"IQIRVO\u00ae Highlights of prescribing information","year":"2024"},{"key":"10.1016\/j.jhep.2025.10.022_bib8","article-title":"PPAR agonists for the treatment of cholestatic liver diseases: over a decade of clinical progress","volume":"9","author":"Hayes","year":"2024","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.jhep.2025.10.022_bib9","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.10.022_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2025.09.016","article-title":"Phase II INTEGRIS-PSC trial of bexotegrast, an \u03b1v\u03b26\/\u03b1v\u03b21 integrin inhibitor, in primary sclerosing cholangitis","volume":"84","author":"Hirschfield","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.022_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2007.11.021","article-title":"Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies","volume":"48","author":"Popov","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.10.022_bib12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1164\/rccm.202403-0636OC","article-title":"Bexotegrast in patients with idiopathic pulmonary fibrosis: the INTEGRIS-IPF study","volume":"210","author":"Lancaster","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jhep.2025.10.022_bib13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825026054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825026054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:01:36Z","timestamp":1765818096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825026054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0168827825026054"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.10.022","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II clinical trials in primary sclerosing cholangitis: Making the most of every opportunity?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.04.025","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.09.016","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}